on INNATE PHARMA (EPA:IPH)
Innate Pharma will participate in the Kempen Life Sciences Conference
Innate Pharma, a biotechnology company specializing in cancer immunotherapies, has announced its participation in the Kempen Life Sciences Conference in Amsterdam, from April 15-16, 2026. Members of its management team will hold individual meetings during the event. This conference represents an opportunity for Innate to discuss its advancements in cancer treatments.
Innate Pharma, listed on Euronext Paris and Nasdaq, develops innovative therapeutic antibodies, notably targeting Nectin-4, KIR3DL2, and NKG2A. The company collaborates with giants like Sanofi and AstraZeneca to advance in immuno-oncology.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INNATE PHARMA news